Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
May 30, 2007 17:43:00 (ET)
SOUTH SAN FRANCISCO, May 30, 2007 /PRNewswire-FirstCall via COMTEX/ -- Exelixis, Inc. (EXEL, Trade ) announced today that data from clinical trials of the company's investigational compounds XL880 and XL999 will be presented at the 2007 American Society of Clinical Oncology Annual Meeting (ASCO), which is being held June 1 to 5 in Chicago, Illinois.
-- Data from the Phase I trials of XL880 will be presented and discussed
during the Developmental Therapeutics: Molecular Therapeutics oral
abstract presentation session at 9:00 a.m. CT on Saturday, June 2, in
room E354b. (Abstract #3526)
-- Data from the Phase II trials of XL999 will be presented and discussed
during the Developmental Therapeutics: Molecular Therapeutics poster
session at 8:00 a.m. on Sunday, June 3, in S Hall A2. (Abstract #3591)
Additionally, four abstracts from Phase I studies of XL184 (Abstract #14031), XL647 (Abstract #14044) and Phase II studies of XL880 (Abstract #15601) and XL999 (Abstract #18112) will be published in abstract form but will not be presented at the meeting.
<snip> |
